October 22, 2014 12:41 PM ET

Healthcare Equipment and Supplies

Company Overview of Cerevast Therapeutics, Inc.

Company Overview

Cerevast Therapeutics, Inc., a medical technology company, engages in the development of non-invasive treatments for acute ischemic stroke and other vascular disorders. It offers ClotBust-ER, an operator independent device, which helps in administering ultrasound energy for sonothrombolysis therapy. Cerevast Therapeutics, Inc. was formerly known as WA32609 Inc. The company was founded in 2009 and is headquartered in Redmond, Washington.

12277 134th Court NE

Suite 202

Redmond, WA 98052

United States

Founded in 2009

Phone:

425-821-1939

Fax:

425-821-9313

Key Executives for Cerevast Therapeutics, Inc.

Chief Executive Officer
Age: 48
Chief Financial Officer
Vice President of Operations
Chief Medical Officer
Age: 54
Vice President of Quality
Compensation as of Fiscal Year 2014.

Cerevast Therapeutics, Inc. Key Developments

Cerevast Therapeutics, Inc. Initiates Phase 3 Clotbust ER Clinical Study for the Treatment of Acute Ischemic Stroke

Cerevast Therapeutics, Inc. announced that it has initiated patient enrollment in its Phase 3 clinical trial evaluating the use of the company's proprietary Clotbust ER ultrasonic headframe for the treatment of acute ischemic stroke. This worldwide study intends to enroll up to 800 ischemic stroke patients in a randomized, double-blinded clinical trial designed to evaluate the efficacy and safety of the Clotbust ER ultrasound device when used in combination with standard intravenous thrombolytic therapy (tissue plasminogen activator - tPA/Alteplase). The Clotbust ER Phase 3 clinical study is being conducted at over 60 leading stroke centers in 14 countries worldwide. The trial will enroll ischemic stroke patients with baseline National Institute of Health Stroke Scale (NIHSS) scores of 10 or greater. Patients will be randomized (400 per arm) to either Clotbust ER ultrasound in combination with IV tPA therapy or standard IV tPA therapy alone. The primary endpoint of the study is 90-day functional outcome as measured by the percentage of patients that achieve a modified Rankin (mRS) score of 0-1 at 90 days post-treatment. The study will also evaluate complete vessel recanalization as a secondary endpoint in a subset of patients that undergo pre and post-treatment MRI or CT angiography. Two interim analyses are scheduled to be performed by the study's Data Safety Monitoring Board (DSMB) upon completion of one-third and two-thirds of enrollment.

Similar Private Companies By Industry

Company Name Region
Keystone Dental, Inc. United States
Convaid, Inc. United States
Advanced Instruments, Inc. United States
Primus Corporation United States
E.V.A. Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
November 13, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cerevast Therapeutics, Inc., please visit www.cerevast.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.